Next Article in Journal
Aquaporins in the Colon as a New Therapeutic Target in Diarrhea and Constipation
Next Article in Special Issue
Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type
Previous Article in Journal
Leptin Receptor Metabolism Disorder in Primary Chondrocytes from Adolescent Idiopathic Scoliosis Girls
Previous Article in Special Issue
Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(7), 1169; doi:10.3390/ijms17071169

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

1
Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Turin 10060, Italy
2
Department of Oncology, University of Torino, Turin 10060, Italy
These authors contributed equally to the work.
*
Author to whom correspondence should be addressed.
Academic Editor: M. Rita I. Young
Received: 20 June 2016 / Revised: 8 July 2016 / Accepted: 14 July 2016 / Published: 20 July 2016
View Full-Text   |   Download PDF [400 KB, uploaded 20 July 2016]   |  

Abstract

Epithelial ovarian cancer (EOC) is the leading cause of death for gynecological cancer. The standard treatment for advanced stage is the combination of optimal debulking surgery and platinum-based chemotherapy. Nevertheless, recurrence is frequent (around 70%) and prognosis is globally poor. New therapeutic agents are needed to improve survival. Since EOC is strongly immunogenic, immune checkpoint inhibitors are under evaluation for their capacity to contrast the “turn off” signals expressed by the tumor to escape the immune system and usually responsible for self-tolerance maintenance. This article reviews the literature on anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies in EOC and highlights their possible lines of development. Further studies are needed to better define the prognostic role of the immune checkpoint inhibitors, to identify predictors of response and the optimal clinical setting in EOC. View Full-Text
Keywords: ovarian cancer; immune checkpoint inhibitor; ipilimumab; nivolumab; pembrolizumab; cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); programmed cell death-1 (PD-1); programmed cell death ligand-1 (PD-L1); tumor infiltrating lymphocytes (TILs) ovarian cancer; immune checkpoint inhibitor; ipilimumab; nivolumab; pembrolizumab; cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); programmed cell death-1 (PD-1); programmed cell death ligand-1 (PD-L1); tumor infiltrating lymphocytes (TILs)
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Mittica, G.; Genta, S.; Aglietta, M.; Valabrega, G. Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? Int. J. Mol. Sci. 2016, 17, 1169.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top